Directorate Change
("Renalytix" or the "Company")
Renalytix Announces Change to Board of Directors
The Company has begun a process to appoint a non-executive director and committee chair successors.
The Board and the executive team would like to thank Ann for her dedication and contribution to the Company during her time as a non-executive director.
For further information, please contact:
|
||||
|
Via Walbrook PR |
|||
|
|
|||
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|||
|
|
|||
|
|
|||
|
Tel: 020 7597 4000 |
|||
|
|
|||
|
|
|||
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|||
|
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
|||
|
|
|||
|
Tel: 415-389-6400 or investors@renalytix.com |
|||
|
|
|
||
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The Company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the